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OBJECTIVES We report on the procedural and six-month results of the first percutaneous and stand-alone
study on myocardial repair with autologous skeletal myoblasts.
BACKGROUND Preclinical studies have shown that skeletal myoblast transplantation to injured myocardium
can partially restore left ventricular (LV) function.
METHODS In a pilot safety and feasibility study of five patients with symptomatic heart failure (HF) after
an anterior wall infarction, autologous skeletal myoblasts were obtained from the quadriceps
muscle and cultured in vitro for cell expansion. After a culturing process, 296  199 million
cells were harvested (positive desmin staining 55  30%). With a NOGA-guided catheter
system (Biosense-Webster, Waterloo, Belgium), 196  105 million cells were transendocar-
dially injected into the infarcted area. Electrocardiographic and LV function assessment was
done by Holter monitoring, LV angiography, nuclear radiography, dobutamine stress
echocardiography, and magnetic resonance imaging (MRI).
RESULTS All cell transplantation procedures were uneventful, and no serious adverse events occurred
during follow-up. One patient received an implantable cardioverter-defibrillator after trans-
plantation because of asymptomatic runs of nonsustained ventricular tachycardia. Compared
with baseline, the LV ejection fraction increased from 36  11% to 41  9% (3 months, p 
0.009) and 45  8% (6 months, p  0.23). Regional wall analysis by MRI showed
significantly increased wall thickening at the target areas and less wall thickening in remote
areas (wall thickening at target areas vs. 3 months follow-up: 0.9 2.3 mm vs. 1.8 2.4 mm,
p  0.008).
CONCLUSIONS This pilot study is the first to demonstrate the potential and feasibility of percutaneous
skeletal myoblast delivery as a stand-alone procedure for myocardial repair in patients with
post-infarction HF. More data are needed to confirm its safety. (J Am Coll Cardiol 2003;
42:2063–9) © 2003 by the American College of Cardiology Foundation
Cell transplantation is emerging as a potential novel thera-
peutic approach for the treatment of heart failure (HF).
Initial studies with different cell types have shown promis-
ing results of cell transplantation in ischemic animal models.
See page 2070
Most preclinical experience has been reported on transplan-
tation of skeletal myoblasts in infarcted myocardium. These
studies demonstrated that transplanted skeletal myoblasts in
damaged myocardium are capable of cellular engraftment,
myotube formation, expression of the slow fiber marker
beta-myosin heavy chain, long-term graft survival, and
augmentation of ventricular function (1–6). As a result of
the outcomes of these animal studies, a pilot safety and
feasibility study on percutaneous transplantation of autolo-
gous skeletal myoblasts by transendocardial injection as a
stand-alone procedure in five patients with ischemic HF
was completed. We report on the procedural and six-month
follow-up results.
PROCEDURE
Objectives. The primary objectives of this pilot study are
feasibility and safety at six months. The secondary objective
was to assess improvement of the left ventricular (LV)
function by iterative investigations at baseline and one,
three, and six months. The protocol was approved by the
local medical ethics committee, and written, informed
consent was obtained from all patients.
Patient selection. Only symptomatic patients with New
York Heart Association functional class II under optimal
medical therapy were selected. All patients were known to
have a previous anterior wall myocardial infarction and
depressed LV function (left ventricular ejection fraction
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[LVEF] between 20% and 45% by radionuclide radiogra-
phy). Myocardial infarction had to be 4 weeks old at the
time of implantation. The presence and location of a
myocardial scar were defined by: akinesia or dyskinesia at
rest during echocardiography, LV angiography, and mag-
netic resonance imaging (MRI); no contractile reserve
during dobutamine stress echocardiography (DSE); and
hyperenhancement by gadolinium on the MRI scan. Exclu-
sion criteria for myoblast injections were: target region wall
thickness5 mm by echocardiography or MRI; a history of
syncope or sustained ventricular tachycardia or fibrillation or
(potential candidate for) implantable cardioverter-
defibrillator (ICD) placement; and positive serologic test
results for human immunodeficiency virus, hepatitis B or C,
or syphilis.
Muscle biopsy. Biopsy of the quadriceps muscle was done
under local anesthesia. On average, 8.4 g (range 5 to 13 g)
of muscle biopsy was excised through a 10-cm-long surgical
incision. All five biopsy procedures were uneventful and
done on an outpatient basis. Biopsies were placed in a bottle
containing a proprietary solution designed to preserve the
biopsy during controlled shipment. The bottle was put in an
insulated thermobox with frozen and refrigerated gel packs
to maintain temperatures between 2°C and 8°C during
transit. The transport conditions were monitored by the use
of a programmable temperature monitor (Sensitech, Bev-
erly, Massachusetts). The container was sent to clinical
Good Manufacture Practice (BioWhittaker, Cambrex
Corp., Walkersville, Maryland) for myoblast cell isolation
and expansion. The average transit duration was 41 h (range
35 to 50 h); no temperature excursions were noted.
Cell-culturing process. On receipt at the culturing facility,
the biopsies were processed according to the Myocell
protocols by Bioheart Inc. The biopsy was minced finely and
then dissociated using digestive enzymes. The dissociated
tissue was washed several times and filtered until a single-
cell suspension was achieved. The expansion culture was
initiated when the cells were plated into sterile tissue culture
flasks in growth media for skeletal muscle myoblasts. The
media were changed at regular intervals; the cells were
harvested and replated according to cell confluence param-
eters. Final harvest was done after three to five passages.
Myoblasts were identified using an immunohistochemical
marker specific for desmin (DAKO) to identify cells com-
mitted to a myogenic differentiation. Specific cell lot release
specifications (cell viability, cell identity, and sterility tests)
were established before the start of the trial, which, if not
met, would result in a re-biopsy of the patient and re-
initiation of the culture process. In three patients a re-biopsy
was required due to the desmin staining results falling below
the lot release criteria. In these patients, a prestimulation
procedure was performed using multiple needle punctures of
the muscle three days before the biopsy procedure to
increase the percentage of myoblast cells in the muscle
biopsy (7).
After a culturing period of 17 days (range 14 to 19 days),
the harvested cells were formulated in a specially designed
transport/injectate media and transferred into a sterile
30-ml bag and sent to our hospital. Shipment was done
under the same controlled conditions as after biopsy. The
transit time averaged 62 h (range 24 to 96 h), and no
temperature excursions were noted. The cells have been
validated for having a 96-h shelf life under controlled
conditions.
Transplantation procedure. The transplantation proce-
dure was scheduled the day after arrival of the cells. Cell
transplantation was done in the cardiac catheterization
laboratory. Access was obtained through the femoral artery,
and 100 IU/kg heparin was given. The target activated
clotting time was between 250 s and 300 s and was regularly
checked every half hour. After a coronary and biplane LV
angiogram (left anterior oblique [LAO] 60° and right
anterior oblique [RAO] 30°) was obtained, an outline of the
LV chamber was drawn on transparent tabloids that were
taped to the fluoroscopy monitors. Then an electromechan-
ical NOGA map (8) of the LV was obtained using a 7F
NOGASTAR catheter (F-curve) connected to the NOGA
console (Biosense-Webster, Waterloo, Belgium). Areas ex-
hibiting low voltages and linear local shortening (unipolar
voltage 4 mV and linear local shortening 4%) on the
NOGA map were considered as the target areas of treat-
ment if these areas were geographically concordant with the
scar areas assessed by the preprocedural DSE, MRI, and LV
angiogram. We refrained from transendocardial injections
into areas with a known wall thickness 5 mm by MRI.
With an 8F MYOSTAR (Biosense-Webster) injection
catheter, 16  4 (mean  SD; range 9 to 19) transendo-
cardial injections were made. The catheter has nitinol
tubing that ends in a 27-gauge retractable needle. Depend-
ing on the average wall thickness of the target region, the
needle length was set at 4.5 to 6.0 mm when the catheter tip
had a 90° curve. By connecting a 1-ml Luer-Lok syringe to
the injection port, the catheter was preloaded with the
skeletal myoblast solution. After establishing stable endo-
myocardial contact on the NOGA map and fluoroscopy, the
needle was advanced manually, which often caused ventric-
ular extra beats. Whenever a regular electrocardiographic
(ECG) rhythm resumed with persisting, stable endomyo-
cardial contact, injections of 0.3 ml (16.6 million cells) were
Abbreviations and Acronyms
DSE  dobutamine stress echocardiography
ECG  electrocardiogram
HF  heart failure
ICD  implantable cardioverter-defibrillator
LAO  left anterior oblique
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
MRI  magnetic resonance imaging
NSVT  non-sustained ventricular tachycardia
RAO  right anterior oblique
TDI  tissue Doppler imaging
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made. Only the first patient received 0.1-ml injections (2.5
million cells) because of the limited volume of myoblast
solution. Injection sites were marked on the NOGA map
(Fig. 1) and the transparent tabloids. Spacing between
injection sites was approximately 1.0 cm apart. After the
injection procedure, a control biplane LV angiogram was
obtained. Afterward, patients were ECG monitored for
18 h, and cardiac enzymes were checked twice at 6- to 8-h
intervals. In all five cases, the in-hospital stay was unevent-
ful, and the patients were discharged within 24 h after the
procedure.
Methods of assessment. At baseline and one, three, and
six months of follow-up, 24-h ambulant ECG monitoring
and DSE with pulsed-wave tissue Doppler imaging (TDI)
were done. The DSE and TDI procedures were performed
with a Hewlett-Packard Sonos 5500 (Andover, Massachu-
Figure 1. NOGA maps (left  unipolar voltage maps; right  linear local shortening maps) in the right anterior oblique (top) and anteroposterior
(bottom) views of Patient no. 2 after 19 injections with autologous skeletal myoblasts in the anteroseptal and anterior myocardial scar and border zone. The
myocardial scar is indicated in red on the unipolar voltage map (6 mV) and on the local linear shortening map (2%). The black dots indicate the
transendocardial injection sites.
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setts) imaging system equipped with second harmonic
imaging to optimize endocardial border detection and
performed as previously described (9,10). In short, after
baseline echocardiography, dobutamine was infused at a
starting dose of 5 g/kg/min for 5 min, followed by 10
g/kg/min for 5 min (low-dose stage). Dobutamine was
then increased by 10 g/kg/min every 3 min up to a
maximum dose of 40 g/kg/min. Atropine (1 to 2 mg) was
added at the end of the last stage if the target heart rate had
not been achieved. Images were acquired continuously and
recorded on tape at the end of every dose step. In addition,
the baseline, low-dose, peak stress, and recovery images
(standard apical and short-axis views) were displayed in a
cine loop format. Wall motion was scored according to the
criteria of the American Society of Echocardiography by
two experienced reviewers blinded to the MRI data for
systolic wall thickening. Pulsed-wave TDI was performed
with a Hewlett-Packard Sonos 5500, and a transducer
operating at frequencies of 1.8 or 2.1 MHz with a pulse
repetition frequency of 45 to 60 kHz was used. Using a
six-segment model, pulsed-wave TDI was performed close
to the mitral annulus in the apical four-chamber, apical
two-chamber, and apical three-chamber views with high
temporal resolution (4  3 ms; range 1 to 7). The depth of
the sample volume was kept constant in each patient during
DSE. A sample volume with a fixed length of 4 mm was
used. The ECG and phonocardiogram were simultaneously
recorded with the pulsed-wave TDI velocity profile and
stored on videotape. The peak pulsed-wave TDI velocity
amplitude of the ejection phase and early and late diastole
were measured off-line using a computer-assisted drawing
system, and the values were expressed in cm/s (10). Five
consecutive beats were analyzed, and the mean velocity
values were calculated to minimize the measurement vari-
ability determined by respiration. The E/A ratio was also
calculated. Cardiac cycles with extrasystolic or postextrasys-
tolic beats or any disturbance of the rhythm were excluded.
Recordings and measurements were repeated at baseline and
at a low-dose (10 g/kg/min) dobutamine infusion rate.
Furthermore, at baseline and three and six months of
follow-up, the LV volume and LVEF were assessed by
biplane LV angiography and technetium-99m–labeled
erythrocyte radionuclide scintigraphy. Biplane LV angiog-
raphy was done in the LAO 60° and RAO 30° projections
with 100-ml sphere calibration in the isocenter. Quantita-
tive analysis was performed using CAAS II software (Pie
Medical, Maastricht, The Netherlands). Also, at baseline
and three-month follow-up, a MRI scan of the heart was
obtained. The studies were performed on a 1.5-T whole-
body MRI system (Sonata, Siemens, Erlangen, Germany).
Patients were placed in a supine position with a four-
channel quadrature body phased-array coil placed over the
thorax. For quantitative analysis, multiple parallel short-axis
slices covering the heart from base to apex were obtained
using a ECG-triggered breath-hold cine gradient-echo
sequence. Imaging parameters were: repetition time of 3.2
ms, echo time of 1.6 ms, and flip angle 65°, which resulted
in a temporal resolution of 47 ms. Quantitative analysis was
performed using standardized software (Argus Siemens,
Erlangen, Germany). Endocardial and epicardial contours
were traced using semi-automatic software to calculate the
LV volumes and LVEF. Each short-axis image was divided
into eight segments of 45°, which resulted in 64 to 80
segments per patient, depending on the number of short-
axis slices covering the heart from base to apex. Regional
wall thickening was calculated for each segment by subtract-
ing the end-diastolic wall thickness from the end-systolic
wall thickness. Delayed contrast-elucidated MRI images
were used to identify transmural and nontransmural infarcts
using a three-dimensional inversion-recovered gradient
echo sequence 15 min after injection of 0.1 mmol
gadolinium-based contrast agent.
RESULTS
Baseline patient characteristics and cell-culturing results are
summarized in Table 1. No procedural complications oc-
curred. Only in one patient (Patient no. 5) was minor
elevation of creatine kinase and its MB fraction (2 times
upper level) and troponin T (0.16 g/l) noted after the
procedure.
During follow-up, Patient no. 3 needed to be hospitalized
at six weeks after the procedure due to progressive HF and
long asymptomatic runs of non-sustained ventricular tachy-
cardia (NSVT) on Holter monitoring. After recompensa-
tion, telemetry still showed NSVT, and an ICD was
implanted prophylactically. In the other four patients, no
adverse events or ventricular arrhythmias were observed.
Table 1. Patient and Cell Culture Characteristics
Pt.
No.
Gender,
Age (yrs)
Previous
Anterior AMI
(years ago)
NYHA
Class
Patent
LAD
Known
Arrythmias
Cells at
Harvest
 106
Cells
Injected
 106
Desmin
Staining
(%)
Cell
Viability
(%)
Potency
(%)
1 F, 78 6 III Yes PAT runs 25 25 85 98 90
2 M, 53 3 II/III Yes PAT runs 544 293 12 97 20–40
3 M, 55 11 III/IV No* PAF, NSVT runs† 183 183 54 95 70
4 M, 59 7 III Yes No 211 211 80 95 100
5 M, 49 2 III Yes No 382 270 44 98 40
*LAD filled by collateral channels. †Asymptomatic, 8 complexes.
AMI  acute myocardial infarction; LAD  left anterior descending coronary artery; NSVT  non-sustained ventricular tachycardia runs; NYHA  New York Heart
Association; PAF  paroxymal atrial fibrillation; PAT  paroxymal atrial tachycardia.
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Global LV function results at three- and six-month
follow-up are summarized in Table 2. Compared with
baseline, angiographic LVEF at three months increased
from 36  11% to 41  9% (p  0.009). This increase in
LVEF, however, was not observed by nuclear or MRI
assessment at three-month follow-up. At six-month follow-
up, both angiographic and nuclear LVEF assessments
showed a trend toward increased LVEF (36 11% to 45
8% [p  0.23] and 38  8% to 45  11% [p  0.07],
respectively).
The MRI analysis of regional wall thickening showed a
descriptive shift toward more regional wall thickening in the
target segments and less regional wall thickening in the
remote hyperkinetic segments (Figs. 2 and 3). By comparing
the marked injection sites on the NOGA map and the
fluoroscopy sheets with the MRI segments, 87 of the 304
MRI segments (all 5 patients) were identified as injected
segments. Paired analysis of these injected segments showed
significantly increased wall thickening at follow-up (0.9 
2.3 mm at baseline vs. 1.8 2.4 mm at 3-month follow-up,
p  0.008).
In all five patients at baseline, DSE showed no signs of
ischemia or ventricular tachycardias. Compared with base-
line, the TDI results of the target anteroseptal and anterior
wall showed a trend toward increased contraction velocity at
six-month follow-up (anteroseptal wall: 5.4  1.9 cm/s vs.
6.1 0.8 cm/s at rest and 8.8 3.4 cm/s vs. 9.1 2.5 cm/s
at low-dose dobutamine; anterior wall: 5.2  1.9 cm/s vs.
5.9  0.7 cm/s at rest and 6.7  1.7 vs. 7.5  1.6 cm/s at
low-dose dobutamine).
DISCUSSION
Treatment of ischemic HF remains a problem. A significant
proportion of patients with congestive HF remain symp-
tomatic despite maximal medication. Alternative therapies,
including surgical cardiomyoplasty, resynchronization ther-
apy, LV assist device, and cardiac transplantation, have their
own indications and limitations. Cell transplantation has
emerged as a potential new treatment strategy. Different cell
types have been used for transplantation in initial preclinical
experiments, but to date, most experience has been accu-
mulated with skeletal myoblasts. There are several features
that make skeletal myoblasts an attractive cell type for
cardiac cell transplantation. Skeletal myoblasts can easily be
obtained in sufficient quantity directly from the patient
(autologous), negating the problems of organ shortage,
ethical concerns, and immunosuppressive therapy. Skeletal
myoblasts are relatively more resistant to ischemia than
cardiomyocytes, thus favoring cellular engraftment within
the ischemic or infarcted myocardium. Furthermore, the
capillary density of infarcted myocardium resembles the
environment in which normal skeletal muscle is obtained.
The biopsy procedure is mildly invasive, and patients can be
discharged within 1 h after the procedure. Although skeletal
myoblasts are not cardiomyocytes, in vitro studies and in
vivo observations have shown that these cells can transformTa
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into contractile cells with expression of beta-myosin heavy
chain, like cardiomyocytes (6,11). The major limitation,
however, is the lack of evidence of electromechanical cou-
pling between the grafted myoblasts and the native cardio-
myocytes in vivo (11), as well as the potential danger of
inducing a reentry circuit for ventricular arrhythmias by the
formed grafted myotubes in the scarred myocardium. It is
known that skeletal myoblasts lose their capability to express
major adhesion and gap junction proteins like N-cadherin
and connexin-43, which are essential for electromechanical
coupling, when the cells differentiate into myotubes (11).
We report on the first five percutaneous and stand-alone
cellular cardiomyoplasty procedures as a potential new
treatment modality for ischemic HF. In post-myocardial
infarction patients with LVEF45% and symptoms of HF,
autologous skeletal myoblasts were injected into the scarred
myocardium by an injection catheter. No periprocedural
complications occurred, and during a 3- to 12-month
follow-up period, in one case, an ICD was implanted at 2
months based on a prophylactic indication because of
asymptomatic NSVT runs. At three-month follow-up, in all
five patients, a significant moderate increase in global LV
function by LV angiography was noted. This angiographic
LVEF improvement, however, was not consistently ob-
served in all patients by nuclear or MRI assessment. Because
MRI and, to a lesser extent, radionuclide angiography have
Figure 2. Changes in regional wall thickening for all 304 magnetic resonance imaging segments. The open and solid bars indicate the number of segments
with wall thickening at baseline and three-month follow-up (FU), respectively. Compared with baseline, less segments showed thinning and more segments
showed moderate thickening at three-month follow-up, and less segments with greater wall thickening were observed at that point.
Figure 3. Cumulative distribution of regional wall thickening segments by magnetic resonance imaging at baseline (open circles) and three-month
follow-up (). At follow-up, there was a descriptive shift toward less thinning and moderate thickening in the target regions and less thickening in the
normokinetic and hyperkinetic remote areas, indicating a kind of left ventricular remodeling.
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been recently recognized as the most reliable and accurate
methods for assessment of LV dimensions and function
(12,13), cellular cardiomyoplasty efficacy studies focusing on
change in LVEF should incorporate one or both of these
techniques.
Regional analysis by MRI showed a significant increase in
wall thickening at the target areas at three-month follow-up
in all five patients. This paradox between equal global and
improved regional LV function is probably explained by the
remodeling of the LV, in which regional improvement of
injected dyskinetic and akinetic segments is counterbalanced
by less thickening of the hypercontractile remote segments,
as seen by MRI. Potentially, less neurohormonal stimula-
tion after treatment may also have occurred, resulting in less
vigorous contraction of normal segments and less dyskinesia
of infarcted segments. One of the limitations in our func-
tional assessment is the missing information on the pulse-
pressure double product at the different assessment time
points. Pressure-volume loop and neurohormonal marker
measurements in future may overcome this limitation.
Feasibility and safety. We cannot draw firm conclusions
from this initial experience, but we believe that catheter-
based cell transplantation in HF patients is feasible and that
the transendocardial catheter-based cell delivery technique
is safe from a procedural point of view. An important
question about potential arrhythmogenic properties of skel-
etal myoblast transplantation is still unanswered. Although
no syncope or malignant arrhythmias were observed in our
pilot study, we have observed in two consecutive follow-up
studies on catheter-based autologous skeletal myoblast
transplantation in eight patients, two sudden deaths and
three ventricular arrhythmias (one symptomatic and two
asymptomatic) within three months after the procedure
(unpublished data, P. C. Smits, 2003). These serious
adverse events necessitated elementary changes in the pro-
tocols of the consecutive studies. Currently, both phase 1
follow-up studies have restarted with enrollment of patients
with ICDs and rigorous rhythm monitoring before and after
the procedure.
Also, Menasche´ et al. (14) have reported four ICD
implantations within one month after the procedure in a
phase 1 trial involving transepicardial autologous skeletal
myoblast injections during bypass surgery in 10 post-
myocardial infarction patients with an average baseline
LVEF of 23%. However, the arrhythmogenic incidents
observed in this study and in other skeletal myoblast cell
transplantation studies may also reflect the natural course of
this high-risk population for arrhythmias. Furthermore, the
likelihood of finding a non-sustained ventricular arrhythmia
recording on serial Holter monitoring is 40% in patients
with HF (15). Therefore, the question remains unanswered
whether skeletal myoblast transplantation is arrythmogenic
and safe.
From this initial experience, we conclude that catheter-
based cell transplantation with autologous skeletal myo-
blasts for the treatment of ischemic HF is feasible and
promising. However, extensive pre- and post-procedural
monitoring studies for arrhythmias and well-defined func-
tional parameters are needed to evaluate the safety and
efficacy of cellular cardiomyoplasty procedures in the near
future.
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